Accessibility Statement

2022 Updates: Lilly's Global COVID-19 Response

November 30, 2022    Posted by: Eli Lilly and Company

article-header-scientist-in-lab-shutterstock-728262253 CAR #1616

NOTE: For more information about Lilly's COVID-19 therapies authorized for emergency use, contact the Lilly COVID Hotline at 1-855-LillyC19 (1-855-545-5921).

  • Lilly continues to closely monitor the COVID-19 pandemic and its global impact. As this is an evolving topic, Lilly will include relevant announcements and information on this page.

  • If the COVID-19 pandemic has impacted your ability to afford or access your Lilly medicine, contact us via these options.

  • Patients and physicians can visit the U.S. Health & Human Services (HHS) Therapeutics Distribution locator to find a potential treatment location.

Lilly has utilized the full force of its expertise to develop novel antibodies that have helped prevent hospital and death in certain individuals with COVID-19. Lilly’s purpose is to create medicines that make life better across key therapeutic areas, as well as COVID-19.  

Learn more about Lilly's past efforts to fight COVID-19.

News Releases, Resources and Multimedia